Inhibition of COX-2 activity by NSAIDs is advantageous in delaying the onset of the disease among patients with familial adenomatos polyposis (FAP) who develop colon cancer in early adulthood due to the loss of ability to inhibit the Wnt/β-catenin pathway [34], whose polyps contain high levels of COX-2 [35]. The gene discussed is PTGS2; the disease is malignant colon neoplasm.